Cambridge, MA, United States of America

Mohammed Ghonime

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations by Mohammed Ghonime in Genetic Engineering

Introduction

Mohammed Ghonime is a prominent inventor based in Cambridge, MA (US), known for his significant contributions to the field of genetic engineering. He holds a total of four patents that focus on enhancing the functionality and persistence of genetically engineered T cells. His work has the potential to revolutionize cancer treatment and immunotherapy.

Latest Patents

Ghonime's latest patents involve genetically engineered T cells that feature disruptions in the Regnase-1 and/or TGFBRII genes. These innovations lead to improved cell growth activity, enhanced persistence, and reduced T cell exhaustion. Additionally, the engineered T cells exhibit enhanced cytotoxicity activity and resistance to inhibitory effects induced by TGF-b and fibroblasts. Such advancements mark a significant step forward in the development of more effective immunotherapies.

Career Highlights

Ghonime is currently associated with Crispr Therapeutics AG, a company at the forefront of gene editing technology. His work there focuses on applying CRISPR technology to develop innovative therapies that can address various medical challenges. His contributions have been instrumental in advancing the understanding and application of genetic modifications in T cells.

Collaborations

Ghonime collaborates with notable colleagues, including Mary-Lee Dequeant and Demetrios Kalaitzidis. Their combined expertise fosters a collaborative environment that enhances the research and development of groundbreaking therapies.

Conclusion

Mohammed Ghonime's innovative work in genetic engineering, particularly in the realm of T cell modifications, showcases his commitment to advancing medical science. His patents and collaborations reflect a dedication to improving therapeutic outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…